Wuhan YZY Biopharma Co., Ltd. (YZYBIO-B) disclosed that on 30 March 2026 it completed the conversion of 61.14 million domestic shares and 6.87 million unlisted foreign shares into a combined 68.01 million H shares. The transaction raises the company’s Hong Kong-listed share count to 179.48 million from 111.47 million, marking a 61.01% expansion in the Exchange-traded float.

Post-conversion, the company’s overall issued share capital remains unchanged at 193.85 million shares, but its composition shifts significantly: • H shares: increased to 179.48 million (previously 111.47 million). • Domestic shares: decreased to 14.37 million (previously 75.51 million). • Unlisted foreign shares: reduced to zero from 6.87 million.

The conversion involves no creation of new shares; rather, it redirects existing domestic and unlisted foreign shares into the H-share category, enhancing market liquidity in Hong Kong while preserving total share capital. All requisite board approvals and regulatory filings have been completed, and the issuer confirms compliance with the Hong Kong Stock Exchange’s Main Board Listing Rules.